Home›Companies›Biotech & Pharma›Petragen

Petragen, Inc.

Develops potential treatments for people with diseases involving abnormal mineral buildup.

Updated Nov 10, 2026·Latest SEC filing Jun 23, 2026·Suggest an edit

About Petragen

Petragen is a private company based in Davie, Florida. It has reported $2,377,307 raised in two offerings on Form D since February 2021. Its chief executive is David Kolb.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Apr 5, 2026Jun 23, 2026$495,000of $1.0M target9$55,000Equity, Common SharesRule 506(b)Form D ↗
Jan 22, 2021Feb 4, 2021amended Feb 16, 2022$1,882,307of $5.0M target39$48,264Equity, Common SharesRule 506(b)Form D/A ↗1 earlier filing
Total, two offerings$2,377,307

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Petragen's Form D filed Jun 23, 2026.

DP
Demetrios Braddock, MD, PhD
CSO and Scientific Founder
David Kolb
David Kolb
CEO, Founder and Chairman

Sources

  1. SECPetragen, Inc. Form D, filed Feb 4, 2021
  2. SECPetragen, Inc. filing history